Xspray Pharma Q1 2024: Reveal of XS025 and PDUFA is nearing - Redeye

Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report. The company has recently raised SEK100m through TO6, unveiled XS025 targeting cabozantinib, and the Dasynoc PDUFA date is less than three months away. We raise our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1006061/xspray-pharma-q1-2024-reveal-of-xs025-and-pdufa-is-nearing?utm_source=finwire&utm_medium=RSS